West Pharmaceutical Servs Azioni (NYSE: WST)

Ultime notizie per West Pharmaceutical Servs (NYSE:WST) Azioni

West Pharmaceutical Servs

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Services Inc

WEST HOLDINGS CORP by West Holdings Corp.

West Holdings Corp

WESTELL TECHS INC A NEW by Westell Technologies, Inc.

Westell Technologies Inc

WESTLIN CORP by Westlin Corp.

WESTERN URANIUM&VANADIUM by Western Uranium & Vanadium Corp.

Western Uranium & Vanadium Corp

WESTPORTS HLDGS BHD ORD by WESTPORTS HLDGS BHD

Westports Holdings Bhd

Wrapped stETH - United States Dollar

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 12.9% since its last report. The company recently reported that it has 1.54 million shares sold short, which is 2.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743192018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 6.60%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About West Pharmaceutical Servs?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Daniel Markowitz initiated coverage on West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with an Outperform rating and announced a price target of $275. West Pharmaceutical shares closed at $231.46 on Monday. <a href="https://www.benzinga.com/quote/WST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) with a Buy rating and announced a price target of $20. Alpha Cognition shares closed at $5.51 on Monday. <a href="https://www.benzinga.com/quote/ACOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Maheep Mandloi initiated coverage on Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Neutral rating and announced a price target of $28. Bloom Energy shares closed at $24.19 on Monday. <a href="https://www.benzinga.com/quote/BE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Joe Flynn initiated coverage on Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy rating and announced a price target of $2.5. Canaan shares closed at $1.07 on Monday. <a href="https://www.benzinga.com/quote/CAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Brian Abrahams initiated coverage on MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with an Outperform rating and announced a price target of $67. MoonLake shares closed at $38.67 on Monday. <a href="https://www.benzinga.com/quote/MLTX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-1024x601.png" alt="" class="wp-image-829880" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

News

Initiation

Markets

Analyst Ratings

ACOG

MLTX

This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Evercore ISI Group analyst Daniel Markowitz initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Outperform rating and announces Price Target of $275.

Price Target

Evercore ISI Group Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $275

March 6, 2025 records indicate that Representative Jared Moskowitz filed a sale of West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), valued between $1,001 and $15,000. According to the March filing, the transaction occurred on March 6, 2025.
Currently, West Pharmaceutical Servs shares are trading down 0.0% at $232.76.
<h3>Representative's Recent Trading Activity</h3>
Over the previous three years, Jared Moskowitz conducted 293 trades, totaling more than $602 thousand. The largest of these were in Raymond James Finl and Seacoast Banking stock. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Jared Moskowitz's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>AbbVie</td>
<td>ABBV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>AbbVie</td>
<td>ABBV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-01-15</td>
</tr>
</tbody>
</table>
Stay informed on Jared Moskowitz's trades and other members of Congress with our real-time <a href="https://www.benzinga.com/gov-trades/members/jared-moskowitz">government trades tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

General

Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stock

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">West Pharmaceutical Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</h3>
<ul>
<li>On Feb. 13, West Pharmaceutical Services reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72. The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $748.8 million, beating the consensus of $740.47 million. The company's stock fell around 39% over the past month and has a <a href="https://www.benzinga.com/quote/WST">52-week low of $197.01</a>.</li>
<li>RSI Value: 21.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>WST Price Action: Shares of West Pharmaceutical gained 2.6% to trade at $208.92 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest WST <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181.png" alt="" class="wp-image-793688" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141453/image-181-768x705.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">Amphastar Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>Amphastar Pharmaceuticals will release results for its fourth quarter results, after the market closes on Thursday, Feb. 27, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. The company's stock fell around 13% over the past month and <a href="https://www.benzinga.com/quote/AMPH">has a 52-week low</a> of $30.34.</li>
<li>RSI Value: 25.3</li>
<li>AMPH Price Action: Shares of Amphastar Pharmaceuticals fell 0.8% to close at $120.92 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1">AMPH stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="857" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182.png" alt="" class="wp-image-793689" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182.png 857w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-300x298.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-150x150.png 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21141606/image-182-768x763.png 768w" sizes="(max-width: 857px) 100vw, 857px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43890670/this-unity-software-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-friday">This Unity Software Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday</a></li>
</ul>

Long Ideas

AMPH

Top 2 Health Care Stocks That May Rocket Higher This Month

A significant insider transaction involving the exercise of company stock options was reported on February 21, by Eric Green, President at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), as per the latest SEC filing.
What Happened: Green, President at West Pharmaceutical Servs, exercised stock options for 0 shares of WST stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760225006115//Archives/edgar/data/105770/000112760225006115/0001127602-25-006115-index.htm">U.S. Securities and Exchange Commission</a> on Friday. The exercise price of the options was $0.0 per share.
Currently, West Pharmaceutical Servs shares are trading up 2.21%, priced at $208.15 during Friday's morning. This values Green's 0 shares at $0.
<h3>Delving into West Pharmaceutical Servs's Background</h3>
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>Understanding the Numbers: West Pharmaceutical Servs's Finances</h3>
Positive Revenue Trend: Examining West Pharmaceutical Servs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.3% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 36.54%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): West Pharmaceutical Servs's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.79.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 30.44 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 5.19 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 19.55, West Pharmaceutical Servs's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Decision Unfolding At West Pharmaceutical Servs: Eric Green Exercises Options, Resulting In $0

A substantial insider activity was disclosed on February 21, as Winters, VP at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), reported the exercise of a large sell of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760225006118//Archives/edgar/data/105770/000112760225006118/0001127602-25-006118-index.htm">U.S. Securities and Exchange Commission</a> on Friday showed that Winters, VP at West Pharmaceutical Servs, a company in the Health Care sector, just exercised stock options worth 0 shares of WST stock with an exercise price of $0.0.
The Friday morning market activity shows West Pharmaceutical Servs shares up by 2.21%, trading at $208.15. This implies a total value of $0 for Winters's 0 shares.
<h3>Unveiling the Story Behind West Pharmaceutical Servs</h3>
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>West Pharmaceutical Servs: Delving into Financials</h3>
Revenue Growth: West Pharmaceutical Servs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 2.3%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 36.54%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): West Pharmaceutical Servs's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.79.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: West Pharmaceutical Servs's P/E ratio of 30.44 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 5.19, West Pharmaceutical Servs's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 19.55, West Pharmaceutical Servs presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chad Winters Decides To Exercise Options At West Pharmaceutical Servs Worth $0

Kimberly MacKay, SVP at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), reported a large exercise of company stock options on February 21, according to a new SEC filing.
What Happened: A notable Form 4 filing on Friday with the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760225006120//Archives/edgar/data/105770/000112760225006120/0001127602-25-006120-index.htm">U.S. Securities and Exchange Commission</a> revealed that MacKay, SVP at West Pharmaceutical Servs, exercised stock options for 0 shares of WST, resulting in a transaction value of $0.
Currently, West Pharmaceutical Servs shares are trading up 2.21%, priced at $208.15 during Friday's morning. This values MacKay's 0 shares at $0.
<h3>Delving into West Pharmaceutical Servs's Background</h3>
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>Understanding the Numbers: West Pharmaceutical Servs's Finances</h3>
Revenue Growth: Over the 3 months period, West Pharmaceutical Servs showcased positive performance, achieving a revenue growth rate of 2.3% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 36.54%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): West Pharmaceutical Servs's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.79.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.11, West Pharmaceutical Servs adopts a prudent financial strategy, indicating a balanced approach to debt management.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 30.44 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 5.19, West Pharmaceutical Servs's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): West Pharmaceutical Servs's EV/EBITDA ratio, lower than industry averages at 19.55, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Exercise Update At West Pharmaceutical Servs: Kimberly MacKay Engages, Resulting In $0

On February 21, it was revealed in an SEC filing that Cindy Reiss-Clark, Chief Commercial Officer at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) executed a significant exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Friday with the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760225006123//Archives/edgar/data/105770/000112760225006123/0001127602-25-006123-index.htm">U.S. Securities and Exchange Commission</a>, Reiss-Clark, Chief Commercial Officer at West Pharmaceutical Servs, exercised stock options for 0 shares of WST. The transaction value amounted to $0.
The latest update on Friday morning shows West Pharmaceutical Servs shares up by 2.21%, trading at $208.15. At this price, Reiss-Clark's 0 shares are worth $0.
<h3>Delving into West Pharmaceutical Servs's Background</h3>
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>West Pharmaceutical Servs's Economic Impact: An Analysis</h3>
Revenue Growth: West Pharmaceutical Servs displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 36.54%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): West Pharmaceutical Servs's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.79.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 30.44 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 5.19 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 19.55 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Engaging In Insider Activity, Cindy Reiss-Clark At West Pharmaceutical Servs Exercises Options Worth $0

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$77.50</td>
<td>$27.5K</td>
<td>206</td>
<td>6.0K</td>
</tr>
<tr>
<td>EYPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$49.7K</td>
<td>431</td>
<td>1.0K</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$100.00</td>
<td>$37.1K</td>
<td>475</td>
<td>384</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$108.00</td>
<td>$38.3K</td>
<td>45</td>
<td>339</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$162.5K</td>
<td>3.5K</td>
<td>222</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$60.00</td>
<td>$110.4K</td>
<td>5.0K</td>
<td>183</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$240.00</td>
<td>$28.4K</td>
<td>5</td>
<td>136</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$257.3K</td>
<td>1.3K</td>
<td>134</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$200.00</td>
<td>$106.5K</td>
<td>203</td>
<td>95</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$550.00</td>
<td>$171.4K</td>
<td>710</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 62 contract(s) at a $77.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.5K, with a price of $445.0 per contract. There were 206 open contracts at this strike prior to today, and today 6063 contract(s) were bought and sold. 
• For EYPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), we notice a put option sweep that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $5.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $49.7K, with a price of $95.0 per contract. There were 431 open contracts at this strike prior to today, and today 1002 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a call option sweep that happens to be bearish, expiring in 304 day(s) on December 19, 2025. This event was a transfer of 24 contract(s) at a $100.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $37.1K, with a price of $1553.0 per contract. There were 475 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be bullish, expiring in 17 day(s) on March 7, 2025. This event was a transfer of 276 contract(s) at a $108.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $38.3K, with a price of $139.0 per contract. There were 45 open contracts at this strike prior to today, and today 339 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 50 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $162.5K, with a price of $3250.0 per contract. There were 3527 open contracts at this strike prior to today, and today 222 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bearish, expiring in 332 day(s) on January 16, 2026. This event was a transfer of 96 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $110.4K, with a price of $1150.0 per contract. There were 5079 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• Regarding WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we observe a call option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 16 contract(s) at a $240.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.4K, with a price of $1780.0 per contract. There were 5 open contracts at this strike prior to today, and today 136 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option sweep with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 83 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $257.3K, with a price of $3100.0 per contract. There were 1316 open contracts at this strike prior to today, and today 134 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on September 19, 2025. Parties traded 82 contract(s) at a $200.00 strike. This particular put needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1300.0 per contract. There were 203 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bullish sentiment. It expires in 3 day(s) on February 21, 2025. Parties traded 40 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $171.4K, with a price of $4285.0 per contract. There were 710 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

EYPT

GILD

TMDX

10 Health Care Stocks Whale Activity In Today's Session

Wall Street ended a two-week losing streak, with the S&amp;P 500 closing just 0.07% below its record high. The rally was fueled by <a href="https://www.benzinga.com/news/global/25/02/43748007/inflation-spikes-in-january-wall-street-rallies-on-ukraine-peace-talks-delayed-tariffs-this-week-in-the-markets">investor optimism despite tariff-related announcements</a> from President Donald Trump and mixed inflation data. 
The S&amp;P 500 gained 1.5%, the Nasdaq surged 2.6%, and the Dow rose 0.5%. Sector-wise, Information Technology led the gains, while Healthcare lagged.
<a href="https://www.benzinga.com/etfs">Among ETFs</a>, five stood out as last week's top performers.
GraniteShares 2x Long SMCI Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCL#NASDAQ">SMCL</a>) soared alongside Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), delivering significant leveraged gains.
<ul>
<li>Weekly Gains: 63.98%</li>
</ul>
<ul>
<li>Focus: Aims to mirror daily investment results of 2 times the daily percentage change of Super Micro Computer.</li>
</ul>
<ul>
<li>Expense Ratio: 1.5%</li>
</ul>
ProShares Ultra Bloomberg Natural Gas ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOIL#NYSE">BOIL</a>) rallied as natural gas prices rebounded from recent lows. 
<ul>
<li>Weekly Gains: 23.75%</li>
</ul>
<ul>
<li>Focus: Offers 2x daily leveraged exposure to natural gas aiming to catch big swings in price over a relatively short period. </li>
</ul>
<ul>
<li>Expense Ratio: 0.95%</li>
</ul>
PLUS Korea Defense Industry Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KDEF#NYSE">KDEF</a>) was propelled by South Korea's growing defense spending. 
<ul>
<li>Weekly Gains: 15.09%</li>
</ul>
<ul>
<li>Focus: Offers investment results that reflects the total return performance of the Korea Defense Industry Index.&nbsp;</li>
</ul>
<ul>
<li>Expense Ratio: 0.65%</li>
</ul>
ProShares Ultra FTSE China 50 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPP#NYSE">XPP</a>) gained on renewed interest in Chinese equities.
<ul>
<li>Weekly Gains: 14.16%</li>
</ul>
<ul>
<li>Focus: Offers 2x daily long leverage to the&nbsp;FTSE/Xinhua China 25 Index. This makes it an ideal tool for investors with a bullish short-term outlook for Chinese equities.</li>
</ul>
<ul>
<li>Expense Ratio: 0.95%</li>
</ul>
ProShares Ultra Semiconductors ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>) benefited from bullish sentiment in chip stocks last week.
<ul>
<li>Weekly Gains: 10.46%</li>
</ul>
<ul>
<li>Focus: Offers 2 times daily long leverage to the Dow Jones U.S. Semiconductors Index.</li>
</ul>
<ul>
<li>Expense Ratio: 0.95% </li>
</ul>
Also Read:<a href="https://www.benzinga.com/government/regulations/25/02/43656846/inflation-rises-more-than-expected-in-january-chills-interest-rate-cut-hopes"> Inflation Rises More Than Expected In January, Chills Interest Rate Cut Hopes</a>
<h2 class="wp-block-heading">What Happened In The Market Last Week?</h2>
Among individual stocks, Super Micro Computer was the biggest gainer in the S&amp;P 500, surging 32%, followed by Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gaining 24%. On the downside, West Pharmaceutical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) fell 33%, leading the week's worst performers.
With investors digesting economic data and global trade developments, attention now shifts to the week ahead, where key earnings reports and macroeconomic events could set the tone for market direction.
Wall Street rebounded after two weeks of losses. Investor sentiment improved despite geopolitical and inflation concerns.
The week also saw Trump announce a 25% tariff on steel and aluminum imports. However, the lack of immediate enforcement helped ease market fears. Inflation data also influenced sentiment, with a hotter-than-expected consumer report midweek offset by a softer producer <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43701823/economists-breathe-sigh-of-relief-why-producer-inflation-isnt-as-bad-as-it-seems">inflation reading on Thursday</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43769585/health-insurance-etfs-in-focus-as-rfk-jr-takes-over-hhs">Health Insurance ETFs in Focus as RFK Jr Takes Over HHS</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

BOIL

INTC

KDEF

SMCI

SMCL

Wall Street Bounces Back: Top-Performing ETFs Of Last Week

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) stock tumbled 33.22% after it reported fourth-quarter results and provided <a href="https://www.benzinga.com//node/43704837" target="_blank" rel="noreferrer noopener">weaker-than-expected 2025 guidance</a>.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) stock dipped 31.66% after the company reported worse-than-expected 2024 fiscal-year fourth-quarter earnings and <a href="https://www.benzinga.com//node/43701094" target="_blank" rel="noreferrer noopener">analysts cut the price forecast</a>.</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) shares fell 17.31% after the company reported fourth-quarter results and several analysts <a href="https://www.benzinga.com//node/43671119" target="_blank" rel="noreferrer noopener">lowered the price forecast</a>.</li>
<li>Comfort Systems USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock declined 14.96%.</li>
<li>Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) shares tumbled 14.06% after the company reported <a href="https://www.benzinga.com//node/43714858" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>. Analysts revised the <a href="https://www.benzinga.com/quote/twlo/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>GoDaddy Inc. (NYSE: GDDY) shares fell 13.82% after the company reported fourth-quarter results and analysts changed <a href="https://www.benzinga.com//node/43736943" target="_blank" rel="noreferrer noopener">their price forecasts</a>.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) stock dived 13.27% after it reported first-quarter financial results <a href="https://www.benzinga.com//node/43637593" target="_blank" rel="noreferrer noopener">and missed its EPS estimate</a>.</li>
<li>Hyatt Hotels Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) fell 12.97% last week following a <a href="https://www.benzinga.com//node/43699989" target="_blank" rel="noreferrer noopener">Q4 earnings miss</a>. Analysts lowered <a href="https://www.benzinga.com/quote/H/analyst-ratings" target="_blank" rel="noreferrer noopener">their price forecast</a> on the stock.</li>
<li>Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares tanked 12.81% after the company reported fourth-quarter results and several <a href="https://www.benzinga.com//node/43709134" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) shares fell 12.51% after it <a href="https://www.benzinga.com//node/43556594" target="_blank" rel="noreferrer noopener">reported quarterly earnings</a>. Analysts revised the <a href="https://www.benzinga.com/quote/ui/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Zebra Technologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) stock decreased 12.40% after the company <a href="https://www.benzinga.com//node/43705227" target="_blank" rel="noreferrer noopener">reported results for the fourth quarter</a>. Many analysts <a href="https://www.benzinga.com/quote/zbra/analyst-ratings" target="_blank" rel="noreferrer noopener">trimmed the price forecasts</a>.</li>
</ol>
Photo via Shutterstock

Equities

Large Cap

Movers

ALAB

GDDY

RDDT

TWLO

ZBRA

Reddit, GoDaddy & Trade Desk Are Among Top 11 Large-Cap Losers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.00</td>
<td>$26.6K</td>
<td>2.5K</td>
<td>4.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$95.5K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$200.00</td>
<td>$192.0K</td>
<td>55</td>
<td>286</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$153.7K</td>
<td>609</td>
<td>250</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$85.00</td>
<td>$26.1K</td>
<td>2.6K</td>
<td>216</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$50.00</td>
<td>$56.0K</td>
<td>1.3K</td>
<td>201</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$40.1K</td>
<td>13.3K</td>
<td>156</td>
</tr>
<tr>
<td>ARWR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$27.4K</td>
<td>385</td>
<td>110</td>
</tr>
<tr>
<td>WGS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$77.50</td>
<td>$35.0K</td>
<td>176</td>
<td>46</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$100.00</td>
<td>$35.6K</td>
<td>602</td>
<td>30</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a put option sweep that happens to be bullish, expiring in 35 day(s) on March 21, 2025. This event was a transfer of 533 contract(s) at a $8.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $26.6K, with a price of $50.0 per contract. There were 2587 open contracts at this strike prior to today, and today 4649 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option trade that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $95.5K, with a price of $191.0 per contract. There were 1849 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For WST (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), we notice a call option sweep that happens to be bearish, expiring in 308 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $200.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $192.0K, with a price of $4800.0 per contract. There were 55 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we observe a put option trade with bullish sentiment. It expires in 336 day(s) on January 16, 2026. Parties traded 250 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $153.7K, with a price of $615.0 per contract. There were 609 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option trade that happens to be bullish, expiring in 154 day(s) on July 18, 2025. This event was a transfer of 39 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $670.0 per contract. There were 2690 open contracts at this strike prior to today, and today 216 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option trade that happens to be bearish, expiring in 7 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $1120.0 per contract. There were 1300 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on March 21, 2025. Parties traded 59 contract(s) at a $60.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $40.1K, with a price of $680.0 per contract. There were 13329 open contracts at this strike prior to today, and today 156 contract(s) were bought and sold. 
• For ARWR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>), we notice a call option sweep that happens to be bullish, expiring in 126 day(s) on June 20, 2025. This event was a transfer of 100 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $276.0 per contract. There were 385 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
• Regarding WGS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>), we observe a call option trade with neutral sentiment. It expires in 7 day(s) on February 21, 2025. Parties traded 35 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1000.0 per contract. There were 176 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option sweep that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 30 contract(s) at a $100.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $35.6K, with a price of $1177.0 per contract. There were 602 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARWR

EXAS

MRNA

RXRX

SRPT

SWTX

10 Health Care Stocks With Whale Alerts In Today's Session

U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday.
Shares of The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/GT/analyst-ratings">quarterly financial results</a>.
Goodyear Tire &amp; Rubber reported quarterly earnings of 39 cents per share which beat the analyst consensus estimate of 31 cents per share. The company reported quarterly sales of $4.95 billion which beat the analyst consensus estimate of $4.87 billion.
Goodyear Tire &amp; Rubber shares jumped 19.4% to $9.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares jumped 97.7% to $33.94 after Nvidia disclosed a stake of 1.74 million shares in a 13F filing.</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) gained 34.6% to $8.65 following upbeat quarterly earnings.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) gained 23.7% to $9.67 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 20.9% to $1.7900 following upbeat quarterly earnings.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.3% to $20.86.</li>
<li>Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) gained 17.2% to $5.85.</li>
<li>TreeHouse Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) gained 17% to $38.90 following fourth-quarter results.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) climbed 16% to $17.25.</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) gained 15.8% to $163.43 following a quarterly revenue beat. Multiple analysts upgraded the stock following the report.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 15.2% to $100.00 following better-than-expected quarterly financial results.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 14.8% to $32.85.</li>
<li>CAE Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) rose 14.7% to $26.98 after the company reported a year-over-year increase in third-quarter financial results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) gained 13.3% to $52.62 after the company reported better-than-expected quarterly adjusted EPS results and raised its FY25 revenue guidance.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) rose 11.2% to $221.56.</li>
<li>Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) gained 9.6% to $57.07.</li>
<li>Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) rose 5.3% to $13.43</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

Intraday Update

ABNB

BEAM

DKNG

PACB

PONY

PSNL

ROKU

UDMY

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Overweight and lowers the price target from $470 to $325.

Keybanc Maintains Overweight on West Pharmaceutical Servs, Lowers Price Target to $325

Investors with a lot of money to spend have taken a bullish stance on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WST, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for West Pharmaceutical Servs.
This isn't normal.
The overall sentiment of these big-money traders is split between 63% bullish and 27%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $282,850, and 4 are calls, for a total amount of $287,220.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $230.0 for West Pharmaceutical Servs during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for West Pharmaceutical Servs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of West Pharmaceutical Servs's whale trades within a strike price range from $210.0 to $230.0 in the last 30 days. 
<h3>West Pharmaceutical Servs Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739553319_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$12.5</td>
<td>$11.5</td>
<td>$11.5</td>
<td>$220.00</td>
<td>$163.3K</td>
<td align="right">218</td>
<td align="right">161</td>
</tr>
<tr>
<td>WST</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$36.1</td>
<td>$32.5</td>
<td>$34.35</td>
<td>$230.00</td>
<td>$68.7K</td>
<td align="right">21</td>
<td align="right">20</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$14.4</td>
<td>$11.2</td>
<td>$12.48</td>
<td>$210.00</td>
<td>$49.9K</td>
<td align="right">76</td>
<td align="right">98</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$39.9</td>
<td>$38.0</td>
<td>$38.0</td>
<td>$210.00</td>
<td>$38.0K</td>
<td align="right">17</td>
<td align="right">23</td>
</tr>
<tr>
<td>WST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$38.5</td>
<td>$36.0</td>
<td>$36.95</td>
<td>$230.00</td>
<td>$36.9K</td>
<td align="right">82</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About West Pharmaceutical Servs</h3>
West Pharmaceutical Services is based in Pennsylvania, us, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
In light of the recent options history for West Pharmaceutical Servs, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of West Pharmaceutical Servs</h3>
<ul>
<li>Currently trading with a volume of 2,011,298, the WST's price is up by 11.88%, now at $222.75. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 69 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest West Pharmaceutical Servs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

West Pharmaceutical Servs's Options Frenzy: What You Need to Know

<h3>Gainers</h3>
<ul>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares rose 64.4% to $0.69 during Thursday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares increased by 41.39% to $0.4. The market value of their outstanding shares is at $11.9 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 29.37% to $16.78. The market value of their outstanding shares is at $134.2 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 23.71% to $0.57. The company's market cap stands at $1.8 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 15.71% to $0.81. The market value of their outstanding shares is at $6.6 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares rose 15.38% to $3.14. The market value of their outstanding shares is at $190.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares fell 24.6% to $243.0 during Thursday's pre-market session. The market value of their outstanding shares is at $17.5 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares decreased by 23.69% to $0.07. The company's market cap stands at $5.4 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock fell 21.08% to $0.21. The market value of their outstanding shares is at $11.3 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 17.57% to $0.24. The company's market cap stands at $7.2 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares decreased by 16.73% to $0.7. The market value of their outstanding shares is at $24.7 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 16.17% to $0.14. The company's market cap stands at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

AIFF

AVGR

CTCX

MBRX

NKGN

OMGA

PLRX

PRPH

TIVC

WINT

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Wall Street climbed on Thursday, even as the Producer Price Index (PPI) sharply exceeded estimates in January, reigniting concerns <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43692996/inflation-fears-mount-as-producer-prices-soar-to-35-put-fed-interest-rate-cut-on-ice">over persistent inflationary pressures. </a>
Despite the hotter-than-expected PPI reading—up 3.5% year-over-year in January, surpassing the 3.3% forecast—investors found some relief in certain PPI components that influence the Federal Reserve's preferred inflation gauge, which showed signs of <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43701823/economists-breathe-sigh-of-relief-why-producer-inflation-isnt-as-bad-as-it-seems">cooling compared to December.</a>
Investor risk appetite remained supported by expectations of ceasefire talks in Ukraine following a conversation between former President Donald Trump and Russian President Vladimir Putin a day earlier. 
By midday trading in New York, all major indices were in positive territory, with technology stocks leading the gains. Among semiconductor stocks, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) continued to rally, surging 10% after strong performances in prior sessions. 
The U.S. chipmaker benefited from renewed buying momentum following comments from Vice President J.D. Vance, who indicated that the Trump administration plans to ease regulations to accelerate AI chip innovation in the U.S.
Intel has now soared over 27% this week, tracking its best weekly performance since 1974. 
The U.S. dollar extended its decline as Treasury yields pulled back sharply, reversing Wednesday&#8217;s surge.
In commodities, gold edged up 0.4% to $2,918 per ounce, oil remained steady at $71 per barrel, and natural gas surged 2.4% to $3.66 per million British thermal units. 
Sentiment in cryptocurrency markets remained subdued, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sliding 2.4% to trade below $96,000.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,903.94</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,088.51</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,493.13</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,261.64</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.6% to $606.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.3% to $445.18.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $532.98.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.4% to $224.58.</li>
<li>The&nbsp;Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 1.1%; the&nbsp;Industrials Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to company earnings reports included:
<ul>
<li>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): up 2.05%</li>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>): down 7.8%</li>
<li>Duke Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>): down 2.5%</li>
<li>American Electric Power Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>): down 0.6%</li>
<li>Equinix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): down 1.9%</li>
<li>Moody's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>): up 2.9%</li>
<li>Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>): down 1.5%</li>
<li>PPL Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>): down 1.8%</li>
<li>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>): up 17.9%</li>
<li>Paycom Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>): flat</li>
<li>HubSpot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>): up 1.6%</li>
<li>Lincoln Electric Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LECO#NASDAQ">LECO</a>): up 11.7%</li>
<li>Curtiss-Wright Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>): down 0.5%</li>
<li>West Pharmaceutical Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>): down 34%</li>
<li>CBRE Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>): up 1.1%</li>
<li>DTE Energy Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>): up 2.4%</li>
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>): up 19.9%</li>
<li>Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>): down 8.8%. </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Photo: Ryan DeBerardinis via Shutterstock

Macro Economic Events

Bonds

Econ #s

Economics

$BTC

CBRE

CROX

CSCO

SPDR Dow Jones Industrial Average ETF Trust

EQIX

GEHC

HUBS

LECO

PAYC

Select Sector SPDR-Consumer Discretionary

Stocks Rise Despite Hot Producer Inflation, Intel Soars, Bitcoin Drops Below $96,000: What's Driving Markets Thursday?

U.S. stocks traded higher toward the end of trading, with the Dow Jones index surging more than 100 points on Thursday.
The Dow traded up 0.33% to 44,514.10 while the NASDAQ rose 0.83% to 19,812.30. The S&amp;P 500 also rose, gaining, 0.52% to 6,083.72.
Check This Out: <a href="https://www.benzinga.com/25/02/43693447/top-wall-street-forecasters-revamp-coinbase-price-expectations-ahead-of-q4-earnings">Top Wall Street Forecasters Revamp Coinbase Price Expectations Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Materials shares jumped by 1.1% on Thursday.
In trading on Thursday, industrials shares fell by 0.2%.
Top Headline
Deere &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) reported better-than-expected earnings for its first quarter.
The company posted a first-quarter 2025 net sales and revenue decline of 30% year-over-year to $8.51 billion, beating the consensus of $7.70 billion.
Net sales were $6.809 billion for the quarter, compared with $10.486 billion in 2024. Deere clocked an EPS of $3.19, down from $6.23 in the prior year, beating the consensus of $3.14.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares shot up 21% to $461.20 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates.</li>
<li>Shares of Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>)got a boost, surging 27% to $82.11 following better-than-expected quarterly financial results.</li>
<li>Edesa Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDSA#NASDAQ">EDSA</a>) shares were also up, gaining 81% to $3.3651. The company announced a $15 million private placement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares dropped 52% to $0.0739 after the company priced a $15 million underwritten public offering.</li>
<li>Shares of The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) were down 33% to $82.17 following downbeat quarterly revenue.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) was down, falling 34% to $213.18 following weak FY25 guidance.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $71.40 while gold traded up 0.6% at $2,945.00.
Silver traded down 0.3% to $32.690 on Thursday, while copper rose 1.5% to $4.7735.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 1.09%, Germany's DAX 40 rose 2.09% and France's CAC 40 rose 1.52%. Spain's IBEX 35 Index rose 0.19%, while London's FTSE 100 fell 0.49%.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 1.28%, China's Shanghai Composite Index falling 0.42%, Hong Kong's Hang Seng Index falling 0.20% and India's BSE Sensex falling 0.04%.
Economics
<ul>
<li>The Producer Price Index surged 3.5% year over year in January, according to Thursday&#8217;s release from the Bureau of Labor Statistics.</li>
<li>U.S. initial jobless claims declined by 7,000 from the previous week to 213,000 during the first week of February, down from market estimates of 215,000.</li>
<li>U.S. natural gas stocks fell 100 billion cubic feet in the week ending Feb. 7, compared to market estimates of a 92 bcf decline.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

Earnings

Eurozone

Commodities

BROS

DGLY

EDSA

Dow Jumps Over 100 Points; Deere Posts Upbeat Earnings

On Thursday,&nbsp;West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) reported a fourth-quarter adjusted EPS of $1.82, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.72</a>.
The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $748.8 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43687013/west-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">consensus of $740.47 million</a>.
The Proprietary Products Segment's sales increased by 3.4% to $613.9 million, and the organic net sales growth was 4.5%.
High-value products (components and devices) represented around 74% of segment net sales, led by customer demand for self-injection device platforms. Fourth-quarter sales included a benefit of approximately $25&nbsp;million in customer incentives earned in connection with volumes achieved related to HVP Delivery Devices.
The Biologics market unit experienced high-single-digit organic net sales growth, driven by an increase in sales of self-injection device platforms, offset by lower sales of NovaPure products.
The Pharma market unit saw mid-single-digit organic net sales growth, driven by an increase in Westar products and Administrative Systems sales.
The Generics market unit had a mid-single digit organic net sales decline, driven by lower volumes of FluroTec products.
Sales in the Contract-Manufactured Products Segment declined by 2.5% to $134.9 million, while organic net sales declined by 2.0%. Segment performance was driven by a continued decrease in sales of healthcare diagnostic devices, partially offset by growth in self-injection devices for obesity and diabetes.
Guidance: West Pharmaceutical Services forecasts 2025 adjusted EPS of $6.00-$6.20 below the consensus of $7.44.
The company expects 2025 revenues of $2.875 billion-$2.91 billion versus a consensus of $3.04 billion.
<ul>
<li>Organic net sales growth is expected to be approximately 2% to 3%.</li>
<li>Net sales guidance includes an estimated full-year 2025 headwind of $75 million based on current foreign currency exchange rates.</li>
</ul>
"Looking ahead to 2025, we expect our business momentum to continue in key areas of our Proprietary Products business, driven by improving High-Value Products trends in Biologics and Generics, and growth driven by Annex 1 and GLP-1. We are focused on operational excellence and driving strong returns in 2025," said Eric Green, President, Chief Executive Officer and Chair.
William Blair writes that West Pharmaceutical stock currently trades at 52.8 times the midpoint of the company's 2025 adjusted EPS guidance.
"Generally speaking, we expect the stock to track to earnings growth that we peg in the low- to midteens long term; however, we believe both 1) that growth profile may not return until mid-to late 2025 and 2) much of the alpha will be recaptured moving into that return-to growth," writes analyst Matt Larew.
William Blair reiterates <a target="_blank" href="https://www.benzinga.com/quote/WST/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action:&nbsp;On Thursday&#8217;s last check, WST stock was down 33.90% at $213.25.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43694603/hertz-misses-on-revenue-profit-as-fleet-shrinks-costs-weigh" target="_blank" rel="noreferrer noopener">Hertz Misses On Revenue, Profit As Fleet Shrinks, Costs Weigh</a></li>
</ul>

Analyst Color

Guidance

Health Care

West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance

Press Releases

West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend

West to Participate in Upcoming Investor Conferences

West Elects New Director to the Board

West Pharmaceutical Services to Present at the CJS 25th Annual "New Ideas for the New Year" Investor Conference

West Introduces Daikyo PLASCAP® RUV Closures in New Nested Format at Pharmapack

Dividends

West Announces First-Quarter Dividend

West to Host Fourth-Quarter and Full-Year 2024 Conference Call

West Announces Fourth-Quarter and Full-Year 2024 Results

West Announces Second-Quarter Dividend

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

West Pharmaceutical Servs

Notizie

Ultime notizie per West Pharmaceutical Servs (NYSE:WST) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO